Skip to main content
Clinical Trials/EUCTR2014-000763-41-ES
EUCTR2014-000763-41-ES
Active, not recruiting
Phase 1

Study of genetic Alzheimer?s disease mutation carriers in preclinical stages of the disease: 18F-Florbetaben Positron Emission Tomography study.

FUNDACIÓ CLÍNIC PER A LA RECERCA BIOMÈDICA0 sites40 target enrollmentJuly 22, 2014

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
FUNDACIÓ CLÍNIC PER A LA RECERCA BIOMÈDICA
Enrollment
40
Status
Active, not recruiting
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 22, 2014
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional clinical trial of medicinal product

Investigators

Sponsor
FUNDACIÓ CLÍNIC PER A LA RECERCA BIOMÈDICA

Eligibility Criteria

Inclusion Criteria

  • 1\. Adult children (\> 18 yo) of genetic Alzheimer?s disease
  • patients with a known mutation in PSEN1, APP o PSEN2
  • genes and who are either cognitively normal (CDR\=0\) or
  • have mild symptoms of cognitive decline (CDR 0\.5 or 1\)
  • 2\. According to the principal investigator, participants must
  • be committed to participate and complete all study
  • procedures.
  • 3\. Has signed the Informed Consent Form voluntarily to
  • participate in the study
  • Are the trial subjects under 18? no

Exclusion Criteria

  • 1\. Subjects that are not able to complete the study.
  • 2\. Any major disease or history of a major disease,
  • especially hepatobilliar disease (AST /ALT ? 5 x ULN) or
  • advanced renal insufficiency (creatinine ? 2 x ULN)
  • 3\. Current or previous history of alcohol abuse or epilepsy
  • 4\. Allergic to Florbetaben or any of its constituents
  • 5\. Multiple drug allergies and/or previous history of contrast
  • 6\. Pregnancy or breast feeding or planned pregnancy during
  • the study period
  • 7\. Any disease or history of disease which, in the opinion of

Outcomes

Primary Outcomes

Not specified

Similar Trials